Literature DB >> 24756315

Colitis associated with biological agents.

K Khirfan1, M Kistin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24756315     DOI： 10.1007/s10620-014-3147-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

Review 1.  Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors:  Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

2.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

3.  Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

Authors:  Joseph A Blansfield; Kimberly E Beck; Khoi Tran; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Suzanne L Topalian; Leah R Haworth; Catherine Levy; Steven A Rosenberg; Richard M Sherry
Journal:  J Immunother       Date:  2005 Nov-Dec       Impact factor: 4.456

4.  Ipilimumab-induced acute severe colitis treated by infliximab.

Authors:  Cecile Pagès; Jean M Gornet; Gentiane Monsel; Matthieu Allez; Philippe Bertheau; Martine Bagot; Celeste Lebbé; Manuelle Viguier
Journal:  Melanoma Res       Date:  2013-06       Impact factor: 3.599

5.  Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Authors:  David R Minor; Kevin Chin; Mohammed Kashani-Sabet
Journal:  Cancer Biother Radiopharm       Date:  2009-06       Impact factor: 3.099

6.  Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.

Authors:  Damien Fouache; Vincent Goëb; Nathalie Massy-Guillemant; Gilles Avenel; Helene Bacquet-Deschryver; Macha Kozyreff-Meurice; Jean-François Ménard; Marc Muraine; Guillaume Savoye; Xavier Le Loët; Christine Tharasse; Olivier Vittecoq
Journal:  Rheumatology (Oxford)       Date:  2009-04-24       Impact factor: 7.580

7.  Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

Authors:  R L Johnston; J Lutzky; A Chodhry; J S Barkin
Journal:  Dig Dis Sci       Date:  2008-12-23       Impact factor: 3.199

8.  Ipilimumab-induced perforating colitis.

Authors:  Kisha A Mitchell; Harriet Kluger; Mario Sznol; Douglas J Hartman
Journal:  J Clin Gastroenterol       Date:  2013-10       Impact factor: 3.062

Review 9.  Colitis associated with biological agents.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.